According to a new report, Johnson & Johnson privately reached out to other makers of the Covid-19 vaccine to ask them to join an effort to study the risks of blood clots but, both Moderna (MRNA) and Pfizer (PFE) declined.
As concerns grew last week over rare cases of blood clots specifically in Johnson & Johnson’s vaccine as well as AstraZenca’s vaccine, the Wall Street Journal reports that J&J asked AstraZeneca (AZN), Pfizer, and Moderna to join its efforts to look into the reports. Pfizer and Moderna executives reportedly declined to participate, saying their vaccines appeared to be safe, according to the Journal’s reporting. AstraZeneca, which has been hurt by reports of blood clots with its vaccine, did agree.
Six women who got J&J’s vaccine developed blood clots, and one woman died. Statistically, the risks are minimal given that more than 7 million doses have been administered and doctors emphasize that the risks of getting blood clots from COVID-19 is far greater than from the vaccines.
Oxford Study Says Similar Risks For Blood Clots with Pfizer, Moderna As With AstraZeneca
An Oxford University study published this week found that number of people who received blood clots after getting vaccinated with a coronavirus vaccines is similar for those who get the Pfizer, Moderna and AstraZeneca vaccine. The AstraZeneca vaccine, which has come under fire in Europe for its associated with blood clots, was produced with Oxford University’s help.
According to the study, 4 in 1 million people experience cerebral venous thrombosis (CVT) after receiving the Pfizer or Moderna vaccine, as opposed to 5 in 1 million people for the AstraZeneca vaccine. The risk, the study concluded, that getting CVT is significantly higher for those who get COVID-19 — 39 out of 1 million people — than it is for those who are vaccinated.
Shares of JNJ were up 0.34% at $160.93 in early Friday trading, as shares of PFE and MRNA traded over a percent higher. Shares of AstraZeneca were down slightly.